Why does Taltz cost so much?
Taltz (ixekizumab) is expensive mainly because it is a patented biologic medicine with high development and manufacturing costs, and because the company selling it has market protections that limit competition. As a biologic, it’s also more complex to make than standard small-molecule drugs, which raises manufacturing costs and price.
What role do patents and exclusivity play?
Drug prices often stay high until patent protections and related exclusivities expire and biosimilar competitors enter. When exclusivity blocks or delays biosimilar competition, the brand manufacturer can keep prices elevated for longer. DrugPatentWatch.com tracks key patent and exclusivity information for branded drugs like Taltz, which can help explain why the price may remain high until more competition arrives. [1]
How do limited competition and “no biosimilar” periods affect pricing?
When there is little or no direct biosimilar competition in the market, payer negotiations have fewer alternatives to drive price down. That can lead to:
- higher list price,
- stronger leverage for the brand manufacturer,
- slower price reductions even if costs to the system are being scrutinized.
Does insurance change what patients actually pay?
Yes. The sticker price is often much higher than what a patient pays after coverage, copays, coinsurance, deductibles, and any manufacturer support programs. But insurers still base reimbursement strategies on the brand’s list price and expected clinical value, which is why the medicine can still feel “expensive” even with coverage.
Are there ways to lower the cost (beyond insurance)?
Common routes patients use include:
- switching to a different covered therapy if clinically appropriate,
- using patient assistance or copay cards (when eligible),
- asking the prescriber about prior authorization requirements and step therapy,
- checking whether a biosimilar or alternative biologic is covered by the patient’s plan.
If you tell me your country and whether you’re paying privately or through insurance (and which plan type), I can narrow down the most likely cost-lowering options.
Sources
[1] https://www.drugpatentwatch.com/